Guilford

Executive Summary

Fourth quarter revenues from sales of the company's Gliadel wafer glioma therapy are projected to be $1.8 mil. in transfer sales and royalties, $700,000 of which are royalties alone, Guilford CEO Craig Smith, MD, told analysts Jan. 12. The company has plans to continue to build Gliadel sales with two potential new indications and a high dose version of the BCNU-containing polymer implant. Guilford and partner Rhone-Poulenc Rorer are conducting a Phase III trial for Gliadel as a first-line therapy, and a Phase II metastatic brain cancer trial